Literature DB >> 15920009

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Wee Joo Chng1, Scott A Van Wier, Gregory J Ahmann, Jerry M Winkler, Syed M Jalal, Peter Leif Bergsagel, Marta Chesi, Mike C Trendle, Martin M Oken, Emily Blood, Kim Henderson, Rafael Santana-Dávila, Robert A Kyle, Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Philip R Greipp, Rafael Fonseca.   

Abstract

Two major genetic categories of multiple myeloma (MM) exist. Hyperdiploid MM (48 to 74 chromosomes, median 53 chromosomes) is associated with trisomies especially of chromosomes 3, 7, 9, 11, 15, and 19, whereas the nonhyperdiploid (< 48 chromosomes or more than 74 chromosomes) MM is associated with primary translocations such as t(11;14), t(4;14), and t(14;16). Whether this dichotomy exists in monoclonal gammopathy of undetermined significance (MGUS) is uncertain due to limitations of current methods in the study of ploidy. This is especially true in MGUS where the number of clonal plasma cells is small. In this study, we derived a fluorescent in situ hybridization (FISH)-based trisomy index from pooled cytogenetic data (karyotype analysis) from 2 large cohorts of patients with MM with abnormal karyotype, and then validated it in 2 independent cohorts of patients who had known ploidy status either by karyotyping or DNA content measurement using flow cytometry. Using the criteria of 2 or more trisomies from a 3-chromosome combination, hyperdiploid myeloma can be detected with high specificity. Applying this index on 28 patients with smoldering multiple myeloma (SMM) or MGUS (11 SMM, 17 MGUS) who had normal karyotype, 11 cases of hyperdiploid SMM/MGUS were detected. This percentage (40%) is remarkably similar to the percentage of hyperdiploid MM reported in the literature, suggesting that hyperdiploid MM may originate early during disease evolution.

Entities:  

Mesh:

Year:  2005        PMID: 15920009      PMCID: PMC1895145          DOI: 10.1182/blood-2005-02-0761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

Authors:  H Avet-Loiseau; J Y Li; N Morineau; T Facon; C Brigaudeau; J L Harousseau; B Grosbois; R Bataille
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

2.  Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance.

Authors:  R Königsberg; J Ackermann; H Kaufmann; N Zojer; E Urbauer; E Krömer; U Jäger; H Gisslinger; S Schreiber; R Heinz; H Ludwig; H Huber; J Drach
Journal:  Leukemia       Date:  2000-11       Impact factor: 11.528

3.  Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition.

Authors:  M Zandecki; J L Laï; F Geneviève; F Bernardi; H Volle-Rémy; O Blanchet; M François; A Cosson; F Bauters; T Facon
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

4.  A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies.

Authors:  G J Ahmann; S M Jalal; A L Juneau; E R Christensen; C A Hanson; G W Dewald; P R Greipp
Journal:  Cancer Genet Cytogenet       Date:  1998-02

5.  Prognostic value of cytogenetics in multiple myeloma.

Authors:  C Seong; K Delasalle; K Hayes; D Weber; M Dimopoulos; J Swantkowski; Y Huh; A Glassman; R Champlin; R Alexanian
Journal:  Br J Haematol       Date:  1998-04       Impact factor: 6.998

6.  The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

Authors:  M M Oken; T Leong; R E Lenhard; P R Greipp; N E Kay; B Van Ness; R M Keimowitz; R A Kyle
Journal:  Cancer       Date:  1999-09-15       Impact factor: 6.860

7.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

Authors:  H Avet-Loiseau; T Facon; A Daviet; C Godon; M J Rapp; J L Harousseau; B Grosbois; R Bataille
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

Review 8.  Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  J Almeida; A Orfao; G Mateo; M Ocqueteau; R García-Sanz; M J Moro; J Hernandez; F Ortega; D Borrego; A Barez; M Mejido; J F San Miguel
Journal:  Pathol Biol (Paris)       Date:  1999-02

9.  Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?

Authors:  P R Greipp; M C Trendle; T Leong; M M Oken; N E Kay; B Van Ness; R A Kyle
Journal:  Leuk Lymphoma       Date:  1999-09

10.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.

Authors:  N V Smadja; C Fruchart; F Isnard; C Louvet; J L Dutel; N Cheron; M J Grange; M Monconduit; C Bastard
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

View more
  34 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

2.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

3.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

Review 5.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 6.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Authors:  Adriana Zingone; W Michael Kuehl
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

7.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Authors:  Fenghuang Zhan; Bart Barlogie; Varant Arzoumanian; Yongsheng Huang; David R Williams; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Maurizio Zangari; Madhav Dhodapkar; John D Shaughnessy
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

8.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

9.  Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Authors:  Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

10.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Authors:  Scott Van Wier; Esteban Braggio; Angela Baker; Gregory Ahmann; Joan Levy; John D Carpten; Rafael Fonseca
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.